It should seem surprising, as interest grows in cannabinoids as health aids and pharmaceuticals, that Information on cannabinoids in breast milk with maternal cannabis use is limited. 

A team at the Oregon Health Sciences University and the University of Utah has recently undertaken to remedy this, quantifying two cannabinoids in the plasma and breast milk of breastfeeding mothers, and assessing the mothers’ cannabis use patterns overall.*

Breast milk, plasma samples, and survey data were collected from 20 volunteer subjects who used cannabis in the previous 48 hours, at 2 weeks and 2 months postpartum. Median age was 27 years. Median instances of cannabis use in the previous 7 days were 17 (6-29) and 23 (15-45) on visits 1 and 2, respectively. Median THC concentrations were 3.7 ng/ml (plasma) and 27.5 ng/ml (breast milk). Median CBD concentrations were  0.6 ng/ml (plasma) and 1.2 ng/ml (breast milk). The median milk:plasma ratios were 7.0 (THC) and 2.6 (CBD). Median breast milk THC concentration increased from visit 1 to visit 2 by 30.2 ng/ml.

THC and CBD accumulate in breast milk relative to plasma. Infant exposure to cannabinoids via breast milk is not known, nor are its effects on infant health.

*Moss MJ, Bushlin I, Kazmierczak S, Koop D, Hendrickson RG, Zuckerman KE, Grigsby TM. Cannabis use and measurement of cannabinoids in plasma and breast milk of breastfeeding mothers. Pediatr Res. 2021 Oct;90(4):861-868. doi: 10.1038/s41390-020-01332-2.

DiolPure products contain PureForm CBD™ transformed from aromatic terpenes for pharmaceutical-grade purity. PureForm CBD™ is bioidentical to CBD extracted from hemp and cannabis, but free of any residual cannabinoids like THC or impurities or chemicals that can associate with traditional plant-derived production processes. 

The foregoing is a report on trends and developments in cannabinoid industry research. No product description herein is intended as a recommendation for diagnosis, treatment, cure or prevention of any disease or syndrome.